Conclusion: This is the largest real-world study describing the association between ADT and the risk of dementia, including over 600 thousand prostate cancer patients. The risk of dementia was significantly higher in patients on ADT, with a 60% increased risk. The highest risk was witnessed with GnRH antagonists (degarelix), with a 92% increased risk. Interestingly, the increased risk of dementia in ADT groups was observed only among whites but not in African Americans. Possible causes of this discrepancy include socioeconomic disparities, bias that resulted in underdiagnosis, or biological differences.
ASCO 2023 Poster: Androgen-deprivatio... - Advanced Prostate...
ASCO 2023 Poster: Androgen-deprivation therapy and risk of dementia in patients with prostate cancer:Clinical outcomes from real-world data.
Written by
rsgdmd
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
great…what I’m on Firmagon (degarelix)
Not what you're looking for?
You may also like...
Exercise in Patients With Prostate Cancer Undergoing Androgen-Deprivation Therapy
fatigued patients. Patients in the lowest quartile regarding reported vitality had the highest fat...
ASCO 2019: Outcomes of Men with Recurrent M0 Prostate Cancer who Defer Androgen Deprivation Therapy until Metastasis
metastasis-free survival (MFS) was 21 years [without ADT] and median overall survival (OS) was 22...
Androgen deprivation therapy for prostate cancer is associated in increased risk for biliary disease
link between androgen depreviation therapy and increased risk for biliary disease....
Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
treated with ADT with follow-up through May of 2016. Exclusions included treatment with ADT for ≤6...
Impact of Androgen-Deprivation Therapy on Self-Reported Cognitive Function in Men With Prostate Cancer
androgen-deprivation therapy (ADT). However, the extent of association between ADT and declines in...